88438
document
Effect of hydrochlorothiazide therapy on cardiac arrhythmias in African-American men with systemic hypertension and moderate to severe left ventricular hypertrophy . The effect of hydrochlorothiazide therapy on ventricular arrhythmias was studied in 45 hypertensive African-American men with moderate to severe left ventricular ( LV ) hypertrophy . After medication washout , patients were treated with placebo followed by hydrochlorothiazide . Clinical , biochemical , and 48-hour ambulatory electrocardiographic data was collected after each treatment phase . Signal-averaged electrocardiograms were recorded in a subgroup of 24 patients . Average LV posterior wall thickness was 15 +/- 1.1 mm , septum 16 +/- 2 mm , LV mass 420 +/- 90 g , and LV mass index 212 = 51 g/m2 . Systolic blood pressure ( BP ) was 168 +/- 18 mm Hg after the placebo phase and 146 +/- 15 mm Hg after hydrochlorothiazide ; diastolic BP was 103 +/- 6 mm Hg and 89 +/- 9 mm Hg , respectively . Serum potassium decreased significantly from 4.2 +/- 0.4 mmol/L to 3.7 +/- 0.6 mmol/L after hydrochlorothiazide therapy . The average hourly incidence of ventricular premature contractions was 22 with placebo and 25 with hydrochlorothiazide . There were 3 and 1 couplets and 0.2 and 0.2 runs of ventricular tachycardia per patient per hour , respectively . Variables of signal-averaged electrocardiography did not differ between the 2 treatments . Thus , in hypertensive African-American men with moderate to severe LV hypertrophy , hydrochlorothiazide does not worsen ventricular arrhythmias or signal-averaged electrocardiographic variables .
88439
Intervention_Pharmacological
hydrochlorothiazide therapy
88440
Intervention_Pharmacological
hydrochlorothiazide therapy
88441
Intervention_Control
placebo
88442
Intervention_Pharmacological
hydrochlorothiazide
88443
Intervention_Pharmacological
hydrochlorothiazide therapy
88444
Intervention_Control
placebo
88445
Intervention_Pharmacological
hydrochlorothiazide
88446
Intervention_Pharmacological
hydrochlorothiazide
88447
Outcome_Other
Effect
88448
Outcome_Physical
cardiac arrhythmias
88449
Outcome_Physical
ventricular arrhythmias
88450
Outcome_Physical
Clinical , biochemical , and 48-hour ambulatory electrocardiographic data
88451
Outcome_Other
Signal-averaged electrocardiograms
88452
Outcome_Physical
Average LV posterior wall thickness
88453
Outcome_Physical
Systolic blood pressure ( BP )
88454
Outcome_Physical
Serum potassium
88455
Outcome_Physical
ventricular premature contractions
88456
Outcome_Physical
ventricular tachycardia
88457
Outcome_Physical
signal-averaged electrocardiography
88458
Outcome_Physical
ventricular arrhythmias
88459
Outcome_Physical
signal-averaged electrocardiographic variables
88460
Participant_Condition
cardiac arrhythmias in African-American men with systemic hypertension and moderate to severe left ventricular hypertrophy
88461
Participant_Sample-size
45 hypertensive African-American
88462
Participant_Sex
men
88463
Participant_Sample-size
with moderate to severe left ventricular ( LV ) hypertrophy
88464
Participant_Sample-size
subgroup of 24 patients
88465
Participant_Condition
hypertensive African-American men with moderate to severe LV hypertrophy